Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy

[1]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[2]  Caicun Zhou,et al.  cGAS-STING, an important pathway in cancer immunotherapy , 2020, Journal of Hematology & Oncology.

[3]  M. Weller,et al.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.

[4]  G. Shapiro,et al.  Biomarker-Guided Development of DNA Repair Inhibitors. , 2020, Molecular cell.

[5]  Zhenzhong Zhang,et al.  Manganese-Based Nano-Activator Optimizes Cancer Immunotherapy via Enhancing Innate Immunity. , 2020, ACS nano.

[6]  S. Manoukian,et al.  Analysis of BRCA1 and RAD51C Promoter Methylation in Italian Families at High-Risk of Breast and Ovarian Cancer , 2020, Cancers.

[7]  Raymond Y Huang,et al.  Mechanisms and therapeutic implications of hypermutation in gliomas , 2020, Nature.

[8]  Ken R. Smith,et al.  Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Park,et al.  Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer , 2020, Nature Communications.

[10]  A. Melcher,et al.  Inflammatory microenvironment remodelling by tumour cells after radiotherapy , 2020, Nature Reviews Cancer.

[11]  A. Warren.  DNA-repair enzyme turns to translation , 2020, Nature.

[12]  J. Coulson,et al.  Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development , 2020, The Journal of pathology.

[13]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[14]  T. Zheng,et al.  STING: a master regulator in the cancer-immunity cycle , 2019, Molecular Cancer.

[15]  K. Camphausen,et al.  Pan-Cancer Analysis of Potential Synthetic Lethal Drug Targets Specific to Alterations in DNA Damage Response , 2019, Front. Oncol..

[16]  Song-Cheol Kim,et al.  Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker. , 2019, European journal of cancer.

[17]  Qiaojun He,et al.  Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses , 2019, Acta pharmaceutica Sinica. B.

[18]  C. Deng,et al.  Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells , 2019, Acta pharmaceutica Sinica. B.

[19]  E. Swisher,et al.  Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. , 2019, JAMA oncology.

[20]  James B. Mitchell,et al.  Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition , 2019, Oncoimmunology.

[21]  A. Tan,et al.  Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. , 2019, JAMA oncology.

[22]  C. Graham,et al.  DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes , 2019, Journal of Immunotherapy for Cancer.

[23]  G. Shapiro,et al.  PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. , 2019, Cancer discovery.

[24]  M. Ladanyi,et al.  Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma , 2019, Genome Medicine.

[25]  Yuzhuo,et al.  BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma , 2019, Genome Medicine.

[26]  A. Melcher,et al.  ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment , 2019, Clinical Cancer Research.

[27]  Tiara Bunga Mayang Permata,et al.  Base excision repair regulates PD-L1 expression in cancer cells , 2019, Oncogene.

[28]  A. Heijink,et al.  BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity , 2019, Nature Communications.

[29]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[30]  M. Rubin,et al.  Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer , 2018, The Journal of clinical investigation.

[31]  T. Mok,et al.  Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade. , 2018, Cancer research.

[32]  T. Conrads,et al.  ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation , 2018, The Journal of clinical investigation.

[33]  C. Drake,et al.  KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). , 2018 .

[34]  K. Kraemer,et al.  Pembrolizumab treatment of a patient with xeroderma pigmentosum with disseminated melanoma and multiple nonmelanoma skin cancers , 2018, The British journal of dermatology.

[35]  A. D’Andrea,et al.  DNA Repair Deficiency and Immunotherapy Response. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[37]  M. O’Connor,et al.  Targeting the replication stress response in cancer. , 2018, Pharmacology & therapeutics.

[38]  M. Berger,et al.  Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Y. Réguerre,et al.  Dramatic response to nivolumab in xeroderma pigmentosum skin tumor , 2018, Pediatric blood & cancer.

[40]  F. Nicolantonio,et al.  Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth , 2017, Nature.

[41]  Tiara Bunga Mayang Permata,et al.  DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells , 2017, Nature Communications.

[42]  Juanita Lopez,et al.  Combining DNA damaging therapeutics with immunotherapy: more haste, less speed , 2017, British Journal of Cancer.

[43]  E. Lander,et al.  A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer , 2017, Nature Genetics.

[44]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[45]  S. Formenti,et al.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. , 2017, The Lancet. Oncology.

[46]  Xiaolian Sun,et al.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment. , 2017, Chemical Society reviews.

[47]  Michael S. Goldberg,et al.  DNA Damage and Repair Biomarkers of Immunotherapy Response. , 2017, Cancer discovery.

[48]  P. Bruzzi,et al.  Excision repair cross complementation group 1 (ERCC-1) gene polymorphisms and response to nivolumab in advanced non-small cell lung cancer (NSCLC). , 2017 .

[49]  Robert Damoiseaux,et al.  Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.

[50]  F. Hirsch,et al.  LAG‐3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD‐1/PD‐L1 and Tumor‐Infiltrating Lymphocytes , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[51]  L. Apetoh,et al.  Rationale for stimulator of interferon genes-targeted cancer immunotherapy. , 2017, European journal of cancer.

[52]  M. Weichenthal,et al.  Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab. , 2017, European journal of cancer.

[53]  Alan Ashworth,et al.  PARP inhibitors: Synthetic lethality in the clinic , 2017, Science.

[54]  P. A. Futreal,et al.  Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance , 2017, Science Translational Medicine.

[55]  A. Nussenzweig,et al.  Endogenous DNA Damage as a Source of Genomic Instability in Cancer , 2017, Cell.

[56]  G. Hortobagyi,et al.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.

[57]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[58]  E. Frangou,et al.  Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. , 2016, The lancet. Gastroenterology & hepatology.

[59]  S. Cairo,et al.  Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents , 2016, Oncotarget.

[60]  M. Salto‐Tellez,et al.  Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer , 2016, Journal of the National Cancer Institute.

[61]  Zhijian J. Chen,et al.  Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing , 2016, Nature Immunology.

[62]  T. Chan,et al.  The role of neoantigens in response to immune checkpoint blockade. , 2016, International immunology.

[63]  G. Bhanot,et al.  Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. , 2016, The Journal of clinical investigation.

[64]  Alberto Martin,et al.  Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored. , 2016, Trends in molecular medicine.

[65]  Y. Matsumoto,et al.  Influence of Ku86 and XRCC4 expression in uterine cervical cancer on the response to preoperative radiotherapy , 2016, Medical Molecular Morphology.

[66]  Lauren L. Ritterhouse,et al.  Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer , 2016, Oncotarget.

[67]  Weihang Chai,et al.  DNA excision repair at telomeres. , 2015, DNA repair.

[68]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[69]  Michael S. Goldberg,et al.  The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. , 2015, Biochemical and biophysical research communications.

[70]  P. Gimotty,et al.  CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer , 2015, Cancer Immunology Research.

[71]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[72]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[73]  P. Hieter,et al.  Mechanisms of genome instability induced by RNA-processing defects. , 2014, Trends in genetics : TIG.

[74]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[75]  I. Dick,et al.  Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity , 2013, PloS one.

[76]  F. Penault-Llorca,et al.  Early Telomere Shortening and Genomic Instability in Tubo-Ovarian Preneoplastic Lesions—Response , 2013, Clinical Cancer Research.

[77]  J. Jiricny.  Postreplicative mismatch repair. , 2013, Cold Spring Harbor perspectives in biology.

[78]  Jiri Bartek,et al.  Replication stress links structural and numerical cancer chromosomal instability , 2013, Nature.

[79]  J. Neal,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  N. Reich,et al.  The DNA Damage Response Induces IFN , 2011, The Journal of Immunology.

[81]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[82]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[83]  Huai-Chin Chiang,et al.  Mutation of NIMA-related kinase 1 (NEK1) leads to chromosome instability , 2011, Molecular Cancer.

[84]  T. Helleday.  Homologous recombination in cancer development, treatment and development of drug resistance. , 2010, Carcinogenesis.

[85]  P. Sung,et al.  Mechanism of eukaryotic homologous recombination. , 2008, Annual review of biochemistry.

[86]  M. Lieber,et al.  The Mechanism of Human Nonhomologous DNA End Joining* , 2008, Journal of Biological Chemistry.

[87]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[88]  B. Quesnel,et al.  Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. , 2007, Blood.

[89]  V. O'shea,et al.  Base-excision repair of oxidative DNA damage , 2007, Nature.

[90]  P. Glazer,et al.  Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia , 2007, Oncogene.

[91]  R. Ward,et al.  The role of MYH and microsatellite instability in the development of sporadic colorectal cancer , 2006, British Journal of Cancer.

[92]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[93]  J. Jiricny.  The multifaceted mismatch-repair system , 2006, Nature Reviews Molecular Cell Biology.

[94]  L. Coussens,et al.  Tumor stroma and regulation of cancer development. , 2006, Annual review of pathology.

[95]  R. Bristow,et al.  Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. , 2005, Cancer research.

[96]  T. Mak,et al.  The Inducible Costimulator Plays the Major Costimulatory Role in Humoral Immune Responses in the Absence of CD28 1 , 2004, The Journal of Immunology.

[97]  P. Glazer,et al.  Decreased Expression of the DNA Mismatch Repair Gene Mlh1 under Hypoxic Stress in Mammalian Cells , 2003, Molecular and Cellular Biology.

[98]  J. Hoeijmakers.  Genome maintenance mechanisms for preventing cancer , 2001, Nature.

[99]  P. Glazer,et al.  Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. , 2000, Cancer research.

[100]  P. Glazer,et al.  Genetic instability induced by the tumor microenvironment. , 1996, Cancer research.

[101]  W. Lambert,et al.  The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. , 1994, Archives of dermatology.

[102]  Z. Herceg,et al.  Histone acetylation by Trrap–Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks , 2006, Nature Cell Biology.